AR030558A1 - COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA, - Google Patents
COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA,Info
- Publication number
- AR030558A1 AR030558A1 ARP010101794A ARP010101794A AR030558A1 AR 030558 A1 AR030558 A1 AR 030558A1 AR P010101794 A ARP010101794 A AR P010101794A AR P010101794 A ARP010101794 A AR P010101794A AR 030558 A1 AR030558 A1 AR 030558A1
- Authority
- AR
- Argentina
- Prior art keywords
- conhch
- alkyl
- cycloalkyl
- aryl
- carbamate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Un compuesto macrocíclico, incluyendo los enantiomeros, estereoisomeros rotámeros y tautomeros de dicho compuesto , así como las sales o solvatos farmacéuticamente aceptables de dicho compuesto, que tiene la estructura general expuesta en la formula (1) en la cual E, X e Y pueden estar independientemente presentes o ausentes y, en caso de estar presentes, son independientemente seleccionados entre las porciones: alquilo, arilo, alquilarilo, heteroarilo, arilheteroarilo, alquilheteroarilo, cicloalquilo, éter alquílico, éter alquilarílico, éter arílico, alquilamino, arilamino, alquilarilamino, alquilsulfuro, alquilarilsulfuro, arilsulfuro, alquilsulfona, alquilarilsulfona, arilsulfona, alquilalquilsulfoxido, alquilarilsulfoxido, alquilamida, arilamida, alquilsufonamida, alquilarilsulfonamida, arilsulfonamida, alquilurea, alquilarilurea, arilurea, carbamato de alquilo, carbamato de alquilarilo, carbamato de arilo, alquilhidrazida, alquilarilhidrazida, alquilhidroxamida, alquilarilhidroxamida, alquilsufonilo, arilsulfonilo, heteroalquilsulfonilo, hetroarilsulfonilo, alquilcarbonilo, arilcarbonilo, heteroarilalquilcarbonilo, heteroarilcarbonilo, alcoxicarbonilo, ariloxicarbonilo, hetoroariloxicarbonilo, alquilaminocarbonilo, arilaminocarbonilo, heteroarilaminocarbonilo, o una combinacion de las mismas; con la condicion de que optativamente E, X, e Y pueden estar sustituidas además con porciones seleccionadas entre el grupo que consiste en aromáticos, alquilo, alquilarilo, heteroalquilo, arilheteroarilo, alquilheteroarilo, cicloalquilo, éter alquílico, éter alquilarílico, alquilsulfuro, alquilarilsulfuro, alquilsulfona, alquilarilsulfona, alquilamida, alquilarilamida, alquilsulfonamida, alquilaminas, alquilarilsulfonamida, alquilurea, alquilarilurea, carbamato de alquilo, carbamato de alquilarilo, halogeno, hidroxilamino, carbazato de alquilo, carbazato de arilo; R1=COR5 o B(OR)2, donde R5=H, OH, OR8NR9R10, CF3, C2F5, C3F7, CF2R6, R6, COR7 donde R7 = H, OH, OR8, CHR9R10, donde R6, R8, R9 y R10 son independientemente seleccionados entre el grupo que consiste en H, alquilo, arilo, heteroalquilo, heteroarilo, cicloalquilo, cicloalquilo, arilalquilo, heteroarilalquilo, CH(R1')COOR11, CH(R1')CONR12R13, CH(R1')CONHCH(R2')COOR11, CH(R1')CONHCH(R2')CONR12R13, CH(R1')CONHCH(R2')CONHCH(R3')COOR11, CH(R1')CONHCH(R2')CONHCH(R3')CONR12R13, CH(R1')CONHCH(R2')CONHCH(R3')CONHCH(R4')COOR11, CH(R1')CONHCH(R2')CONHCH(R3')CONHCH(R4')CONR12R13, CH(R1')CONHCH(R2')CONHCH(R3')CONHCH(R4')CONHCH(R5')COOR11, CH(R1')CONHCH(R2')CONHCH(R3')CONHCHR4')CONHCH(R5')CONR12R13 donde R1', R2', R3', R4,', R5', R11, R12, R13 son independientemente seleccionados entre el grupo que consiste en H, alquilo, arilo, heteroalquilo, heteroarilo, cicloalquilo, alquilarilo, alquilheteroarilo, arilalquilo, y heteroaralquilo; Z es seleccionado entre O, N o CH; W puede estar presente o ausente y, en caso de estar presente W es seleccionado entre C=O, C=S, SO2 o C=NR; Q es (NR)p, O, S, CH2, CHR, CRR' o un enlace doble hacia V; A es O, CH2, (CHR)p, (CHR-CHR')p, (CRR')p, NR, S, SO2, C=O o un enlace; G es (CH2)p, (CHR)p, (CRR')p, NR, O, S, SO2, S(O)2NH, C=O o un enlace doble hacia E o V; V es CH, CR o N; p es un numero de 0 a 6 y R, R', R2, R3, y R4 son independientemente seleccionados entre el grupo que consiste en H, alquilo, C1-10, alquenilo C2-10, cicloalquilo C3-8, heterocicloalquilo C3-8, arilo, alcoxi, ariloxi, alquiltio, ariltio, amino, amido, éster, ácido carboxílico, carbamato, urea, cetona, aldehído, ciano, nitro, heteroarilo, alquilarilo, alquilheteroarilo, (cicloalquil)alquilo y (heterocicloalquil)alquilo, donde dicho cicloalquilo se compone de tres a ocho átomos de carbono y de cero a seis átomos de oxígeno, nitrogeno, azufre o fosforo y dicho alquilo es de uno a seis átomos de carbono; donde dichas porciones alquilo, heteroarilo, alquenilo, heteroalquenilo, arilo, heteroarilo cicloalquilo y heterocicloalquilo pueden estar optativamente sustituidas, y donde dicho término "sustituido" se refiere a una sustitucion optativa y adecuada con una o más opciones seleccionadas entre el grupo que consiste en alquilo, alquenilo, alquinilo, arilo, aralquilo, cicloalquilo, heterocíclico, halogeno, hidroxi, tio, alcoxi, ariloxi, alquiltio, ariltio, amino, amido, éster, ácido carboxílico, carbamato, urea, cetona, aldehído, ciano, nitro, sulfonamida, sulfoxido, sulfona, sulfonilurea, hidrazida e hidraxamato y tiourea; así como métodos para la preparacion de dichos compuestos. En otra realizacion, también se describen composiciones farmacéuticas que comprenden dichos macrocíclicos así como su uso para la cloracion de un medicamento en el tratamiento de trastornos asociados con la proteasa de VHC, inhibidores de la reina proteasa NS-3 del virus de la hepatitis C.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19820400P | 2000-04-19 | 2000-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR030558A1 true AR030558A1 (es) | 2003-08-27 |
Family
ID=22732422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010101794A AR030558A1 (es) | 2000-04-19 | 2001-04-17 | COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA, |
Country Status (22)
Country | Link |
---|---|
US (1) | US6914122B2 (es) |
EP (1) | EP1274724A2 (es) |
JP (1) | JP4748912B2 (es) |
KR (1) | KR20020097220A (es) |
CN (3) | CN1432022A (es) |
AR (1) | AR030558A1 (es) |
AU (1) | AU2001253621A1 (es) |
BR (1) | BR0110104A (es) |
CA (1) | CA2406532A1 (es) |
CZ (1) | CZ20023473A3 (es) |
HK (1) | HK1048479A1 (es) |
HU (1) | HUP0302957A2 (es) |
IL (1) | IL151935A0 (es) |
MX (1) | MXPA02010375A (es) |
NO (1) | NO20025030L (es) |
NZ (1) | NZ521456A (es) |
PE (1) | PE20011288A1 (es) |
PL (1) | PL358591A1 (es) |
RU (1) | RU2002131163A (es) |
SK (1) | SK14952002A3 (es) |
WO (1) | WO2001081325A2 (es) |
ZA (1) | ZA200208014B (es) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ298749B6 (cs) | 1996-10-18 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
AU3659102A (en) * | 2000-12-12 | 2002-06-24 | Schering Corp | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
EP1707571B1 (en) | 2001-01-22 | 2011-09-28 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CN100381440C (zh) * | 2002-04-11 | 2008-04-16 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3-ns4蛋白酶的抑制剂 |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
EA009295B1 (ru) | 2003-05-21 | 2007-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединения в качестве ингибиторов вируса гепатита с |
US8921521B2 (en) | 2003-06-18 | 2014-12-30 | Ocera Therapeutics, Inc. | Macrocyclic modulators of the Ghrelin receptor |
US7521420B2 (en) | 2003-06-18 | 2009-04-21 | Tranzyme Pharma, Inc. | Macrocyclic antagonists of the motilin receptor |
US20090198050A1 (en) * | 2003-06-18 | 2009-08-06 | Tranzyme Pharma Inc. | Macrocyclic Modulators of the Ghrelin Receptor |
US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
MXPA06002250A (es) | 2003-08-26 | 2006-05-17 | Schering Corp | Inhibidores peptidomimeticos novedosos de la serina proteasa ns3 del virus de la hepatitis c. |
MY148123A (en) * | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
PE20050431A1 (es) | 2003-09-22 | 2005-07-19 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c |
JP4525982B2 (ja) * | 2003-09-26 | 2010-08-18 | シェーリング コーポレイション | C型肝炎ウイルスのns3セリンプロテアーゼの大環状インヒビター |
AU2004282148A1 (en) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US8187874B2 (en) * | 2003-10-27 | 2012-05-29 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
JP2007532479A (ja) | 2003-11-20 | 2007-11-15 | シェーリング コーポレイション | C型肝炎ウイルスns3プロテアーゼの脱ペプチド化インヒビター |
DE602005025855D1 (de) | 2004-01-21 | 2011-02-24 | Boehringer Ingelheim Pharma | Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus |
JP2008505849A (ja) | 2004-02-04 | 2008-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特に、hcv、ns3−ns4aプロテアーゼの阻害剤 |
US7816326B2 (en) | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
EP1737821B1 (en) | 2004-02-27 | 2009-08-05 | Schering Corporation | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease |
ATE478889T1 (de) | 2004-02-27 | 2010-09-15 | Schering Corp | Neuartige verbindungen als hemmer von hepatitis c-virus ns3-serinprotease |
AU2005222055A1 (en) | 2004-02-27 | 2005-09-22 | Schering Corporation | Compounds as inhibitors of hepatitis C virus NS3 serine protease |
CN103102389A (zh) | 2004-02-27 | 2013-05-15 | 默沙东公司 | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物 |
US7205330B2 (en) | 2004-02-27 | 2007-04-17 | Schering Corporation | Inhibitors of hepatitis C virus NS3 protease |
CN1984922A (zh) | 2004-05-20 | 2007-06-20 | 先灵公司 | 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸 |
ES2366478T3 (es) | 2004-07-20 | 2011-10-20 | Boehringer Ingelheim International Gmbh | Análogos peptídicos inhibidores de la hepatitis c. |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
ATE513844T1 (de) | 2004-08-27 | 2011-07-15 | Schering Corp | Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
WO2007001406A2 (en) * | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
BRPI0610737A2 (pt) * | 2005-06-02 | 2010-07-20 | Schering Corp | formulações farmacêuticas e métodos de tratamento usando as mesmas |
AU2006252519B2 (en) | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
US20110104109A1 (en) * | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
AU2006276246B2 (en) | 2005-07-25 | 2012-09-27 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
PL1913015T3 (pl) * | 2005-07-29 | 2014-04-30 | Janssen R&D Ireland | Makrocykliczne inhibitory wirusa zapalenia wątroby typu C |
ES2401661T3 (es) | 2005-08-02 | 2013-04-23 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
ES2449268T3 (es) * | 2005-08-19 | 2014-03-19 | Vertex Pharmaceuticals Inc. | Procesos |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
UA93990C2 (ru) | 2005-10-11 | 2011-03-25 | Интермюн, Инк. | Соединения и способ ингибирования репликации вируса гепатита c |
EP1951748B1 (en) | 2005-11-11 | 2013-07-24 | Vertex Pharmaceuticals, Inc. | Hepatitis c virus variants |
US7705138B2 (en) * | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
KR20080112303A (ko) | 2006-03-16 | 2008-12-24 | 버텍스 파마슈티칼스 인코포레이티드 | 중수소화 c형 간염 프로테아제 억제제 |
MX2008012225A (es) * | 2006-03-23 | 2008-12-03 | Schering Corp | Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas. |
KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
RU2009109355A (ru) | 2006-08-17 | 2010-09-27 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Ингибиторы вырусной полимеразы |
WO2008048121A2 (en) | 2006-10-18 | 2008-04-24 | Lincoln University | Macrocyclic cysteine protease inhibitors and compositions thereof |
US8557848B2 (en) | 2006-12-22 | 2013-10-15 | Merck Sharp & Dohme Corp. | 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections |
EP2064181A1 (en) * | 2006-12-22 | 2009-06-03 | Schering Corporation | 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
MX2009006877A (es) | 2006-12-22 | 2009-09-28 | Schering Corp | Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos. |
WO2008106058A2 (en) * | 2007-02-27 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US8759353B2 (en) * | 2007-02-27 | 2014-06-24 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
NZ581606A (en) * | 2007-05-03 | 2012-06-29 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
ES2381410T3 (es) | 2007-05-04 | 2012-05-28 | Vertex Pharmceuticals Incorporated | Terapia de combinación paa el tratamiento de infecciones por VHC |
EA200971041A1 (ru) * | 2007-05-10 | 2010-08-30 | Интермьюн, Инк. | Новые пептидные ингибиторы репликации вируса гепатита с |
US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
ATE541845T1 (de) | 2007-08-29 | 2012-02-15 | Schering Corp | 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen |
CN101842353A (zh) * | 2007-08-29 | 2010-09-22 | 先灵公司 | 用于治疗病毒感染的2,3-取代的吲哚衍生物 |
ES2447543T3 (es) | 2007-08-29 | 2014-03-12 | Merck Sharp & Dohme Corp. | Derivados de indol sustituidos y métodos de utilización de los mismos |
US8492546B2 (en) * | 2007-08-30 | 2013-07-23 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
CN102099351A (zh) * | 2007-11-16 | 2011-06-15 | 先灵公司 | 3-杂环取代的吲哚衍生物及其使用方法 |
US8377928B2 (en) * | 2007-11-16 | 2013-02-19 | Merck Sharp & Dohme Corp. | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
TW201518507A (zh) * | 2007-12-21 | 2015-05-16 | Celgene Avilomics Res Inc | Hcv蛋白酶抑制劑及其用途(二) |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8778877B2 (en) | 2007-12-21 | 2014-07-15 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US8003659B2 (en) * | 2008-02-04 | 2011-08-23 | Indenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
CA2705300A1 (fr) * | 2008-02-15 | 2009-06-04 | Xeda International | Macrocyclic inhibitors of hepatitis c protease |
US8372802B2 (en) | 2008-03-20 | 2013-02-12 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors |
KR20110005869A (ko) * | 2008-04-15 | 2011-01-19 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제 |
EP2303893B1 (en) * | 2008-06-13 | 2016-12-07 | Merck Sharp & Dohme Corp. | Tricyclic indole derivatives |
US8697694B2 (en) | 2008-08-20 | 2014-04-15 | Merck Sharp & Dohme Corp. | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
CA2734487A1 (en) | 2008-08-20 | 2010-02-25 | Southern Research Institute | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
US8715638B2 (en) | 2008-08-20 | 2014-05-06 | Merck Sharp & Dohme Corp. | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
AR072938A1 (es) | 2008-08-20 | 2010-09-29 | Southern Res Inst | Derivados de piridina y pirimidina azosustituidos y su uso en el tratamiento de infecciones virales |
JP2012514605A (ja) | 2009-01-07 | 2012-06-28 | サイネクシス,インコーポレーテッド | Hcvおよびhiv感染の治療への使用におけるシクロスポリン誘導体 |
US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
EP2435424B1 (en) | 2009-05-29 | 2015-01-21 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
WO2011025849A1 (en) * | 2009-08-27 | 2011-03-03 | Merck Sharp & Dohme Corp. | Processes for preparing protease inhibitors of hepatitis c virus |
CN105001302A (zh) * | 2009-09-28 | 2015-10-28 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
US20120276047A1 (en) | 2009-11-25 | 2012-11-01 | Rosenblum Stuart B | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
AR079528A1 (es) | 2009-12-18 | 2012-02-01 | Idenix Pharmaceuticals Inc | Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c |
CA2785488A1 (en) | 2009-12-22 | 2011-07-21 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
EP2536410B1 (en) | 2010-02-18 | 2015-09-23 | Merck Sharp & Dohme Corp. | Substituted pyrimidine derivatives and their use in treating viral infections |
MA34147B1 (fr) | 2010-03-09 | 2013-04-03 | Merck Sharp & Dohme | Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales |
CN103025736B (zh) * | 2010-06-07 | 2016-07-06 | Abbvie公司 | 大环的丙型肝炎丝氨酸蛋白酶抑制剂 |
JP2013541499A (ja) | 2010-07-26 | 2013-11-14 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法 |
JP2013540122A (ja) | 2010-09-29 | 2013-10-31 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法 |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
EP2489669A1 (en) * | 2011-02-18 | 2012-08-22 | Helmholtz-Zentrum für Infektionsforschung GmbH | Haprolid and derivatives thereof as inhibitors of HCV |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
WO2012142085A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
EP2755981A4 (en) | 2011-09-14 | 2015-03-25 | Merck Sharp & Dohme | HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES |
HUE054006T2 (hu) | 2011-12-28 | 2021-08-30 | Chugai Pharmaceutical Co Ltd | Eljárás peptid vegyület ciklizálására |
JP5860197B1 (ja) * | 2013-01-09 | 2016-02-16 | ギリアード サイエンシーズ, インコーポレイテッド | ウイルス感染症を処置するための治療用化合物 |
EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
EP3063140A4 (en) | 2013-10-30 | 2017-11-08 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
JP7020910B2 (ja) | 2015-03-13 | 2022-02-16 | 中外製薬株式会社 | 改変アミノアシルtRNA合成酵素およびその用途 |
JP7229158B2 (ja) | 2017-06-09 | 2023-02-27 | 中外製薬株式会社 | N-置換アミノ酸を含むペプチドの合成方法 |
EP3694508A4 (en) * | 2017-10-11 | 2021-11-24 | Cornell University | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS |
US11492369B2 (en) | 2017-12-15 | 2022-11-08 | Chugai Seiyaku Kabushiki Kaisha | Method for producing peptide, and method for processing bases |
KR20210098476A (ko) | 2018-11-30 | 2021-08-10 | 추가이 세이야쿠 가부시키가이샤 | 펩티드 화합물 또는 아마이드 화합물의 탈보호법 및 고상 반응에 있어서의 탈수지 방법, 및 펩티드 화합물의 제조 방법 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5377083A (en) * | 1976-12-16 | 1978-07-08 | Asahi Chem Ind Co Ltd | Penicillins and their derivatives |
US4260601A (en) * | 1979-10-23 | 1981-04-07 | Nyegaard & Co. A/S | Chemical compounds |
FI77875C (fi) * | 1982-11-26 | 1989-05-10 | Nyegaard & Co As | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptider. |
US4956344A (en) * | 1987-09-17 | 1990-09-11 | Hafslund Nycomed A/S | Method for treatment of lesions in the large intestinal epithelium with a tripeptide |
CN1074422C (zh) | 1987-11-18 | 2001-11-07 | 希龙股份有限公司 | 制备含有hcv表位的分离多肽的方法 |
DK0381216T3 (da) | 1989-02-01 | 1996-05-13 | Asahi Glass Co Ltd | Azeotrop eller azeotroplignende chlorfluorcarbonhydridblanding |
EP0527788B1 (en) | 1990-04-04 | 2004-06-30 | Chiron Corporation | Hepatitis c virus protease |
JPH07228594A (ja) * | 1994-02-18 | 1995-08-29 | Suntory Ltd | エンドセリン受容体拮抗ペプチド |
IL109943A (en) * | 1994-06-08 | 2006-08-01 | Develogen Israel Ltd | Conformationally constrained backbone cyclized peptide analogs |
WO1998007734A1 (en) | 1996-08-21 | 1998-02-26 | Hybridon, Inc. | Oligonucleotide prodrugs |
CZ298749B6 (cs) | 1996-10-18 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
JP4452401B2 (ja) * | 1997-08-11 | 2010-04-21 | ベーリンガー インゲルハイム (カナダ) リミテッド | C型肝炎ウイルス阻害ペプチドアナログ |
AP1117A (en) * | 1998-04-15 | 2002-11-02 | Aventis Pharma Inc | Process for the preparation of resin-bound cyclic peptides. |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6407066B1 (en) * | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
-
2001
- 2001-04-17 CN CN01810566A patent/CN1432022A/zh active Pending
- 2001-04-17 CZ CZ20023473A patent/CZ20023473A3/cs unknown
- 2001-04-17 WO PCT/US2001/012530 patent/WO2001081325A2/en active IP Right Grant
- 2001-04-17 NZ NZ521456A patent/NZ521456A/en unknown
- 2001-04-17 RU RU2002131163/04A patent/RU2002131163A/ru not_active Application Discontinuation
- 2001-04-17 IL IL15193501A patent/IL151935A0/xx unknown
- 2001-04-17 CN CNA2009100067369A patent/CN101580536A/zh active Pending
- 2001-04-17 EP EP01927142A patent/EP1274724A2/en not_active Withdrawn
- 2001-04-17 KR KR1020027013965A patent/KR20020097220A/ko not_active Application Discontinuation
- 2001-04-17 PE PE2001000348A patent/PE20011288A1/es not_active Application Discontinuation
- 2001-04-17 SK SK1495-2002A patent/SK14952002A3/sk not_active Application Discontinuation
- 2001-04-17 HU HU0302957A patent/HUP0302957A2/hu unknown
- 2001-04-17 JP JP2001578418A patent/JP4748912B2/ja not_active Expired - Fee Related
- 2001-04-17 AU AU2001253621A patent/AU2001253621A1/en not_active Abandoned
- 2001-04-17 PL PL01358591A patent/PL358591A1/xx not_active Application Discontinuation
- 2001-04-17 AR ARP010101794A patent/AR030558A1/es unknown
- 2001-04-17 MX MXPA02010375A patent/MXPA02010375A/es active IP Right Grant
- 2001-04-17 BR BR0110104-8A patent/BR0110104A/pt not_active IP Right Cessation
- 2001-04-17 US US09/836,636 patent/US6914122B2/en not_active Expired - Fee Related
- 2001-04-17 CA CA002406532A patent/CA2406532A1/en not_active Abandoned
- 2001-04-17 CN CNA2006101537103A patent/CN1935833A/zh active Pending
-
2002
- 2002-10-04 ZA ZA200208014A patent/ZA200208014B/en unknown
- 2002-10-18 NO NO20025030A patent/NO20025030L/no not_active Application Discontinuation
-
2003
- 2003-01-18 HK HK03100478.8A patent/HK1048479A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA02010375A (es) | 2003-04-25 |
CN1432022A (zh) | 2003-07-23 |
HUP0302957A2 (hu) | 2003-12-29 |
IL151935A0 (en) | 2003-04-10 |
WO2001081325A2 (en) | 2001-11-01 |
AU2001253621A1 (en) | 2001-11-07 |
ZA200208014B (en) | 2004-02-12 |
CZ20023473A3 (cs) | 2003-01-15 |
CA2406532A1 (en) | 2001-11-01 |
SK14952002A3 (sk) | 2003-03-04 |
KR20020097220A (ko) | 2002-12-31 |
CN1935833A (zh) | 2007-03-28 |
NZ521456A (en) | 2004-07-30 |
HK1048479A1 (zh) | 2003-04-04 |
PL358591A1 (en) | 2004-08-09 |
EP1274724A2 (en) | 2003-01-15 |
WO2001081325A3 (en) | 2002-08-01 |
US20020016294A1 (en) | 2002-02-07 |
BR0110104A (pt) | 2003-01-07 |
JP4748912B2 (ja) | 2011-08-17 |
RU2002131163A (ru) | 2004-06-27 |
PE20011288A1 (es) | 2001-12-12 |
US6914122B2 (en) | 2005-07-05 |
CN101580536A (zh) | 2009-11-18 |
NO20025030D0 (no) | 2002-10-18 |
JP2003531199A (ja) | 2003-10-21 |
NO20025030L (no) | 2002-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR030558A1 (es) | COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA, | |
AR029903A1 (es) | Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas, composiciones farmaceuticas y utilizacion de los mismos para la manufactura de un medicamento | |
AR030249A1 (es) | Peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c, composicion farmaceutica que lo comprende, un metodo para su preparacion y el uso de los mismos para la manufactura de medicamentos y un metodo para modular el procesamiento de un polipeptido del virus | |
AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
JP2003531199A5 (es) | ||
AR043938A1 (es) | Compuesto heterociclico derivado de quinolina o naftiridina, composicion farmaceutica que lo comprende y su uso para preparar esta ultima | |
AR036598A1 (es) | Derivados de 4,5-dihidro-1h-pirazol que tienen potente actividad antagonista de cb1 | |
AR046758A1 (es) | Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c | |
RU2004110719A (ru) | Зздабиторы протеаз, расщепляющих за пролином | |
AR038183A1 (es) | Peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c | |
MY139335A (en) | Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists | |
TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
AR036492A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes | |
NO20073357L (no) | 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien | |
AR043674A1 (es) | Derivados de piridazinona como inhibidores no nucleosidos de la transcriptasa reversa | |
EA200600892A1 (ru) | Новые хинолиновые производные | |
DK0622361T3 (da) | Heterocykliske forbindelser som bradykininantagonister | |
RU2006113880A (ru) | Макроциклические ингибиторы сериновой протеиназы ns3 вируса гепатита с | |
AR038214A1 (es) | Compuestos de prolina como inhibidores de la serina proteasa ns3 del virus de la hepatitis c | |
AR034127A1 (es) | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento | |
MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
NO20072515L (no) | 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav | |
NO20052683L (no) | Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
AR037465A1 (es) | Compuesto derivado de 5-sulfanil-4h-1,2,4-triazol, composicion farmaceutica que lo comprende y proceso para su preparacion en fase liquida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |